Key statistics
On Tuesday, RAPT Therapeutics Inc (RAPT:NMQ) closed at 1.88, 8.67% above its 52-week low of 1.73, set on Sep 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.93 |
---|---|
High | 1.93 |
Low | 1.77 |
Bid | 0.752 |
Offer | 2.00 |
Previous close | 1.88 |
Average volume | 290.55k |
---|---|
Shares outstanding | 34.90m |
Free float | 34.26m |
P/E (TTM) | -- |
Market cap | 65.62m USD |
EPS (TTM) | -3.12 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Announcements
- RAPT Therapeutics Reports Second Quarter 2024 Financial Results
- RAPT Therapeutics Reports First Quarter 2024 Financial Results
- RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
- RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
- RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
- RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
- RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
More ▼